• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Enable Injections inks development deals for wearable drug-delivery device

November 13, 2018 By Sarah Faulkner

Enable Injections on-body injectorEnable Injections said today that it inked development deals with Apellis Pharmaceuticals and UCB for its enFuse on-body drug-delivery device.

The Cincinnati-based company has ongoing partnerships with five companies. Enable Injection’s enFuse device is designed for the subcutaneous delivery of high-volume drugs, including monoclonal antibodies.

“Because enFuse frees patients to self-administer at home, it greatly enhances patient experience and overall patient value,” Jeff Wren, head of UCB’s neurology patient value unit, said in prepared remarks. “enFuse is the right answer for patient needs, which makes it a great addition to our program.”

“We are conducting human clinical trials using the enFuse technology to deliver our novel complement immunotherapies subcutaneously,” Dr. Cedric Francois, co-founder & CEO of Apellis, added. “With our broad therapeutic application, we are excited to partner with Enable to bring promising new therapies with a more patient-centric drug delivery system to patients in need.”

“Pharmaceutical companies racing to improve outcomes and be recognized as patient-centric are realizing the symbiosis between drug and delivery,” Enable Injection’s president & CEO, Michael Hooven, said. “They are partnering with Enable Injections to improve the patient experience, with the aim of increasing adherence and achieving the outcomes necessary for commercial success.”

Last month, Enable Injections closed a $50 million Series B round, led by Sanofi (NYSE:SNY). Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: Enable Injections

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS